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ABSTRACT 
Venlafaxine is a novel antidepressant with a rapid onset of action. It is highly efficacious in the 
treatment of depression and in comparison to the traditional thcyclic antidepressants^ has a favourable 
side effects profile.Although effective, venlafaxine too carries a risk for manic switch in bipolar affective 
disorder patients. Give the paucity of literature, we report a case of venlafaxine induced mania and 
discuss the possible neurochemical underpinnings of this adversity. 
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Because of its quicker onset of action, 
i.e..within a week of initiation,venlafaxine is 
considered as a breakthrough in the treatment of 
depression. This novel bicyclic phenethylamine 
antidepressant has a well proven efficacy in the 
treatment of depression (Montgomery, 1993). 
Similar to tricyclic antidepressants (TCAs), 
venlafaxine too inhibits the reuptakes of 
serotonin,noradrenaline and, to some extent, 
dopamine, but in a dose dependent manner 
(Bezchilbnyk-Butler & Jeffries, 1998; Horst & 
Preskom, 1998). However, in contrast to the TCAs, 
due to lack of anticholinergic, antihitaminergic and 
antiadrenergic effects it is generally better tolerated 
(Montgomery, 1993). 
Bipolar affective disorder is a common and 
disabling disorder. Although mood stabilizers 
remain the treatment of choice for bipolar 
depression, at times, when the depression is 
marked and not improving with mood stabilizers, 
a short course of antidepressant treatment is 
considered (APA,1994). Although effective, 
almost all the antidepressants carry a risk of 
mania/hypomania in bipolar patients. This risk is 
high with the TCAs (Bottlender et al.,1998). A 
similar risk for mania/hypomania has been noted 
with venlafaxine too (Montgomery, 1993 ; Stoner 
etal.,1999). In a review (Montgomery, 1993), 0.04% 
has been proposed as the incidence rate of 
venlafaxine-induced mania. Since venlafaxine-
induced mania has not been reported in Indian 
literature, we report a case and discuss the 
possible neurochemical underpinning of this 
adverse effect of venlafaxine. 
CASE REPORT 
A 45-year old female, having a history of 
unspecified mental illness in her maternal uncle, 
was brought to us with following complaints 
Having had a manic episode 25 years ago, she 
developed a major depressive episode of severe 
intensity with psychotic features six months ago 
Due to lack of improvement, after four months of 
onset of severe depressive episode, she was taken 
to a private psychiatrist. Treatment was initiated 
with venlafaxine 37.5 mg/day, which was increased 
to 150mg/day at the end of first week. Additionally 
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she was also prescribed clonazepam 1 mg at night 
for her sleep and alprazolam SR 0.5 mg at morning 
for her restlessness. Within a fortnight,her 
depressive symptoms started improving steadily. 
At the end of 20 days of therapy,family members 
noted changes in her behaviour. She started talking 
more and became irritable and aggressive. Her 
sleep decreased and she started demanding good 
food. Family members who were unaware of this 
complication did not discontinue venlafaxine until 
they contacted us. 
Patient was brought to us after five weeks 
of her manic symptomatology. Mental status 
examination at the time of consultation revealed 
overactivity, physical and verbal aggresssion, 
distractibility, overabundant speech,elated 
affect,delusions of grandiosity and persecution , 
second person auditory hallucination and absent 
insight. Physical examination revealed 
anteroinferior perforation of right tympanic 
membrance. She was diagnosed as a case of 
bipolar affective disoreder, current episode being 
drug induced mania. Due to severe management 
problems, she was hospitalized. Venlafaxine 
was discontinued and treatment was intiated with 
carbamazepine (200-600 mg/day) and risperidone 
(2-6mg/day). Investigations did not reveal any 
abnormality. Her psychopathology was rated with 
the scale for manic states (Cassidy et al.,1998). 
The total manic score was 55 at admission and it 
dropped to 29,23 and 18 at the end of first, second 
and third week of treatment, respectively. Except 
psychotic items, all other manic items had 
significantly improved at the end of three weeks 
of hospitalization. 
DISCUSSION 
The temporal relationship noted between 
the beginnig of venlafaxine therapy and the onset 
of mania suggests that in our patient venlafaxine 
could be the most probable cause for manic 
switch. Proposed risk factors for antidepressant-
induced mania include female sex, premorbid 
cyclothymic personality and a history suggestive 
of manic proneness (Wehr & Goodwin, 1987). 
Except female sex, we did not observe any of the 
above mentioned risk factors in our patient. Lack 
of addition of a mood stabilizer and a faster titration 
of venlafaxine to 150 mg/day,however,mighthave 
additionally heightened to risk of mania. 
Dose dependent inhibition of the reuptakes 
of major three neurotransmitters is the unique 
feature of venlafaxine. At lower doses, it 
exclusively inhibits serotonin reuptake. At doses 
150 mg/day or above, it inhibits reuptake of both 
serotonin and noradrennaline (Muth et al., 1986) 
and at still higher doses, it blocks dopamine 
reuptake (Bezchilbnyk-Butler & Jeffries, 1998). 
Antidepressant effect of venlafaxine is correlated 
with its serotonin and noradrenaline re-upt inhibition 
whereas the significance of dopamine reuptake 
blockade is presently unknown (Horst & 
Preskorn,1998). 
Both the phenomenology and course of 
manic switch of our patient suggest a few 
interesting conclusions regarding the 
dopaminergic action of venlafaxine. First, severe 
depression of our patient turned into psychotic 
mania within two weeks of venlafaxine 150-mg/ 
day. This finding suggests that probably all three 
neurotransmitter systems, including dopaminergic 
system, as evidenced by psychotic features of 
our case, might have been activated at the doses 
150mg/day . Although this view is contracting to 
the existing data (Bezehiibnyk-Butler & 
Jeffries, 1998), we believe that at least in some 
persons who are prone for switch ,e.g., female 
gender (Wehr& Goodwin ,1987), dopaminergic 
activation may be occurring at moderate doses of 
venlafaxine. Second, although mood, biological, 
cognitive and behavioral symptoms of mania of 
our patient significantly improved within a week of 
discontinuation of venlafaxine, psychotic features 
remained stable even at the end of three weeks of 
treatment. This finding leads to a query that 
whether venlafaxine-induced dopaminergic 
activation lasting longer than that of activation of 
other two neurotransmitter sytems. This argument 
is, at least partly, supported by an earlier 
observation in which mania induced by a 
predominantly dopaminergic antidepressant, 
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bupropion, in a case of recurrent depressive 
disorder, persisted for a long period even after durg 
discontinuation (Bittman & Young,1991). In 
summary, we state that although venlafaxine is 
considered as a safe agent in the treatment of 
women with bipolar II disorder (Amsterdam & 
Garcia-Espana, 2000), its utility in the treatment 
of depression of bipolar I disorder needs further 
evaluation. In addition , the clinical significance of 
venlafaxine induced dopaminergic activation 
should also be explored in detail. The present work 
is a singly case report, hence,welldesigned 
studies are essential to confirm our views. 
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